- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04855630
Combatir el Alzheimer a través del sueño y el ejercicio (CASE)
Combatir el Alzheimer a través del sueño y el ejercicio (CASE)
The Combating Alzheimer's through Sleep and Exercise (CASE) study is an exploratory, hypothesis-generating trial designed to: (1) assess whether improvements in sleep are associated with improvements in cognitive performance and cardiovascular and metabolic health; (2) evaluate the effects of structured, moderate-level aerobic and anaerobic exercise on cognitive performance and cardiovascular and metabolic health; (3) examine the combined, potentially synergistic effects of both interventions on cognitive performance and cardiovascular and metabolic health; and (4) investigate the role of light exposure as a potential modulator of sleep parameters.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Azizi A Seixas, PhD
- Número de teléfono: 3052431301
- Correo electrónico: Azizi.seixas@med.miami.edu
Copia de seguridad de contactos de estudio
- Nombre: Debbie Chung, PhD
- Número de teléfono: 3052431301
- Correo electrónico: dxc1729@miami.edu
Ubicaciones de estudio
-
-
Florida
-
Miami, Florida, Estados Unidos, 33136
- Reclutamiento
- University of Miami Hospitals
-
Contacto:
- Azizi A Seixas, PhD
- Número de teléfono: 3052431301
- Correo electrónico: Azizi.seixas@med.miami.edu
-
Investigador principal:
- Azizi A Seixas, PhD
-
Sub-Investigador:
- Alberto Ramos, MD
-
Contacto:
- Debbie Chung, PhD
- Número de teléfono: 3052431301
- Correo electrónico: dxc1729@miami.edu
-
Sub-Investigador:
- Debbie Chung, PhD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Aged 55-80 years at the time of the screening visit
- Able to ambulate safely and independently
- Able to safely perform moderate-intensity exercise as per the Physical Activity Readiness Questionnaire (PAR-Q, a validated exercise readiness questionnaire)
- Able to wear and use Fitbit wristwatch and/or the Elemind Neuromodulation headband and Lys devices
- Able to operate a digital device like mobile phone or computer
- Able and willing to provide venous blood samples
- Able to understand and speak English (our AR-based MCI diagnosis tool does not yet have capacity for other languages)
- Able to self-report a history of cognitive changes or impairment
- Be cognitively able (including those with and without MCI) and willing to provide informed consent
- Body weight <400 pounds (<181.4kg) in order to safely operate the NuStep T4r Recumbent Stepper stationary bicycle
Exclusion Criteria:
- Severe mobility limitations that prevent safe participation in moderate exercise protocols
- Unstable or uncontrolled medical conditions (e.g., recent cardiovascular event (<6 months), cerebrovascular accident or transient ischemic attack (<6 months), active cancer, or uncontrolled diabetes) that pose safety concerns
- Inability to complete intake screening procedures
- Severe uncorrected hearing impairment-particularly if it precludes effective utilization of the Elemind Neuromodulation headband-and/or vision impairment that interferes with digital device usage or in-person exercise guidance
- Determined to have Alzheimer's/dementia based on performance on the Quick Mild Cognitive Impairment (QMCI).
- Inability or unwillingness to learn or engage with digital devices (e.g., smartphone, Fitbit, Elemind, or Lys), even with staff support
- Regular pre-study engagement in ≥150 minutes of moderate-level and/or ≥75 minutes of vigorous-level exercise per week based on Fitbit data obtained during the initial seven-day onboarding screening period
- Determined to have sufficient sleep, as defined by a sleep efficiency mean of ≥80%) based on Elemind Neuromodulation headband data obtained during the initial seven-day onboarding screening period
- Current usage of disease-modifying therapy targeting amyloid (e.g., anti-amyloid monoclonal antibodies) or tau
- Body weight ≥400 pounds (≥181.4kg), which would pose a safety risk during the operation of the NuStep recumbent stationary bicycle
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Sleep Only Group
Participants in this group will wear the Elemind headband 3-4 times weekly for 8 weeks. |
The Elemind Neuromodulation headband is a wearable device that utilizes noninvasive, electroencephalography-based (EEG-based) technology to induce a sleep state more rapidly via personalized acoustic stimulation. Specifically, the headband uses a closed-loop system, meaning that the headband conveys stimulation based upon recorded neural activity in order to modulate real-time oscillating circuits at the macroscopic level. This device uses five dry, flexible EEG electrodes-including three recording electrodes that are positioned at the Fpz and Fp1/2 electrode sites in accordance with the 10-20 International System of electrode placement and two silicone rubber-based, linked reference electrodes located at the mastoids-to measure neural activity during sleep and provide an estimation of the phases of real-time neural oscillations. The headband generates a sound pulse by identifying alpha neural oscillations in real-time through endpoint-corrected Hilbert Transform algorithm. |
|
Comparador activo: Exercise Only Group
Participants in this group will participate in a structured, on-site, twice a week exercise program for 60 minutes/session for 8 weeks (16 total sessions). Each exercise session is comprised of 60 minutes, including 10 minutes of warm-up, 20 minutes of cardiovascular exercise on a stationary bike, 20 minutes of resistance training (1 day of upper body focus, 1 day of lower body focus each week), and 10 minutes of cooling off). |
Participants randomized to the exercise-only group will engage in an 8-week, home- and site-based exercise intervention designed for older adults across a range of cognitive and physical function levels. All site-based sessions will occur in-person at the study facility under supervision of trained staff. Each week, participants will attend two 60-minute structured exercise sessions, consisting of aerobic training and resistance training. On the remaining five days when subjects will not engage in structured exercise, subjects will be asked to engage in 30 minutes of moderate-intensity walking activities. In-lab exercise protocols will be fully standardized to ensure consistency of exercise dosage and fidelity across participants. The target exercise load will be 270 minutes of moderate-intensity exercise weekly for 8 weeks. |
|
Comparador activo: Exercise and Sleep Group
Participants in this group will take part in the on-site, structured exercise program twice per week for 8 weeks in additional to wearing the Elemind headband 3-4 times per week for 8 weeks. |
The Elemind Neuromodulation headband is a wearable device that utilizes noninvasive, electroencephalography-based (EEG-based) technology to induce a sleep state more rapidly via personalized acoustic stimulation. Specifically, the headband uses a closed-loop system, meaning that the headband conveys stimulation based upon recorded neural activity in order to modulate real-time oscillating circuits at the macroscopic level. This device uses five dry, flexible EEG electrodes-including three recording electrodes that are positioned at the Fpz and Fp1/2 electrode sites in accordance with the 10-20 International System of electrode placement and two silicone rubber-based, linked reference electrodes located at the mastoids-to measure neural activity during sleep and provide an estimation of the phases of real-time neural oscillations. The headband generates a sound pulse by identifying alpha neural oscillations in real-time through endpoint-corrected Hilbert Transform algorithm. Participants randomized to the exercise-only group will engage in an 8-week, home- and site-based exercise intervention designed for older adults across a range of cognitive and physical function levels. All site-based sessions will occur in-person at the study facility under supervision of trained staff. Each week, participants will attend two 60-minute structured exercise sessions, consisting of aerobic training and resistance training. On the remaining five days when subjects will not engage in structured exercise, subjects will be asked to engage in 30 minutes of moderate-intensity walking activities. In-lab exercise protocols will be fully standardized to ensure consistency of exercise dosage and fidelity across participants. The target exercise load will be 270 minutes of moderate-intensity exercise weekly for 8 weeks. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Glycated Hemoglobin (HbA1c) Levels
Periodo de tiempo: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
Total Cholesterol Levels
Periodo de tiempo: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
Triglycerides Levels
Periodo de tiempo: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
High-sensitivity C-reactive protein (hs-CRP) Levels
Periodo de tiempo: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
Low-Density Lipoprotein (LDL) Levels
Periodo de tiempo: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
C-Peptides
Periodo de tiempo: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
High-Density Lipoprotein (HDL) Levels
Periodo de tiempo: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
Cognitive Function
Periodo de tiempo: Up to 8 weeks
|
Cognitive function gauged from Altoida's Digital Neuro-Signatures |
Up to 8 weeks
|
|
Insulin Levels
Periodo de tiempo: Up to 8 weeks
|
Measured from blood sample |
Up to 8 weeks
|
|
Neurofilament light chain
Periodo de tiempo: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Total Sleep Duration
Periodo de tiempo: Up to Week 8
|
Measured from Elemind |
Up to Week 8
|
|
Slow Wave Sleep Duration
Periodo de tiempo: Up to Week 8
|
Measured from Elemind |
Up to Week 8
|
|
%Slow-wave Sleep
Periodo de tiempo: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
Rapid Eye Movement Duration
Periodo de tiempo: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
%REM
Periodo de tiempo: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
Light Non-Rapid Eye Movement Duration
Periodo de tiempo: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
%Light Non-Rapid Eye Movement Sleep
Periodo de tiempo: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
Sleep Efficiency
Periodo de tiempo: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
Sleep Onset Latency
Periodo de tiempo: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
Restlessness (Restless Bouts/Hour during Sleep)
Periodo de tiempo: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Light Exposure
Periodo de tiempo: Up to Week 8
|
Measured by LYS Device |
Up to Week 8
|
|
Psychosocial Metrics
Periodo de tiempo: Up to Week 8
|
Measured by Questionnaires |
Up to Week 8
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Azizi A Seixas, PhD, University of Miami
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Desordenes mentales
- Trastornos neurocognitivos
- Trastornos cognitivos
- Tauopatías
- Enfermedades neurodegenerativas
- Comportamiento
- Disfunción congnitiva
- Enfermedad de Alzheimer
- Demencia
- Actividad del motor
Otros números de identificación del estudio
- 20220931
- 20-01023 (Otro identificador: NYU)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .